Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
1 finding from 1 review
Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion with one dose schedule showed no clear difference in bleeding Number of participants with a significant bleeding event ‐… compared with prophylactic platelet transfusions with another dose schedule (high certainty).
2 findings from 1 review
Bleeding Number of days with significant bleeding ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days with significant bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
2 findings from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes number of participants with a significant bleeding event compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes mortality: secondary to bleeding compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review